Search

Merck’s Darren Verlenden discusses the strategy and ethics behind the expansion plan in Lenexa, Kansas

Editas and Azzur Group scale up their efforts against sickle cell disease with experimental gene editing medicine EDIT-301

Here’s why virus-like particles could open a new chapter in combating disease.

Scientists are targeting EV-A71 RNA viruses using an adeno-associated virus-delivered CRISPR-Cas13 editor

We speak with the BPSA to find out why X-ray sterilization is being considered as an alternative to gamma irradiation

Katalin Karikó and Drew Weissman win prestigious prize for persevering in a field that many ignored.

In light of cabotegravir’s positive opinion for sexually acquired HIV-1, I wanted to explore the history and politics of HIV/AIDS drug development

Experts from Emergent BioSolutions break down the qualities that make an ideal CDMO partner for plasma- based protein manufacturing

Lessons learned in starting up a company – and navigating an industry dominated by men.

Could non-pathogenic viruses provide an unrejectable therapeutic target?